LEO LUZNIK to Retrospective Studies
This is a "connection" page, showing publications LEO LUZNIK has written about Retrospective Studies.
Connection Strength
0.287
-
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023 01 05; 141(1):49-59.
Score: 0.060
-
Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2016; 57(3):666-75.
Score: 0.036
-
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014 Dec 11; 124(25):3817-27.
Score: 0.034
-
Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leuk Lymphoma. 2022 12; 63(12):2987-2991.
Score: 0.015
-
Thrombotic Microangiopathy after Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. Biol Blood Marrow Transplant. 2020 12; 26(12):2306-2310.
Score: 0.013
-
Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study. Biol Blood Marrow Transplant. 2020 09; 26(9):1679-1688.
Score: 0.013
-
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica. 2020 01; 105(1):47-58.
Score: 0.012
-
HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Adv. 2019 09 10; 3(17):2581-2585.
Score: 0.012
-
Haploidentical transplantation using posttransplant cyclophosphamide as GVHD prophylaxis in patients over age 70. Blood Adv. 2019 09 10; 3(17):2608-2616.
Score: 0.012
-
Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 12; 25(12):2431-2437.
Score: 0.012
-
Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes. Biol Blood Marrow Transplant. 2018 10; 24(10):2056-2064.
Score: 0.011
-
Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant. 2017 Feb; 23(2):325-332.
Score: 0.010
-
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults. J Clin Oncol. 2015 Oct 01; 33(28):3152-61.
Score: 0.009
-
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood. 2015 May 07; 125(19):3024-31.
Score: 0.009
-
Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant. 2013 Apr; 19(4):647-52.
Score: 0.008
-
Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institution. Biol Blood Marrow Transplant. 2011 Sep; 17(9):1404-9.
Score: 0.007
-
Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr; 16(4):482-9.
Score: 0.006
-
Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen. Bone Marrow Transplant. 2009 Mar; 43(6):477-80.
Score: 0.006
-
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1279-87.
Score: 0.006